MaxCyte Investor Presentation Deck

MaxCyte Partnerships - Near and Long-Term Revenue Potential with Strong Upside in Commercial Opportunity First Wave 1 Potential Approved Partner Program Launch Potential: 2024 SPL Program: Vertex's Exa-Cel Indications: Sickle Cell Disease Beta-Thalassemia Second Wave 7 Potential Approved Partner Programs Launch Potential: 2025-2027 SPL Programs: SPL Partner A Program 1 SPL Partner A Program 2 Caribou's CB-010 Editas' EDIT-301 Precision Bio's Azer-cel Vor's Trem-cel Invios' APN401 Indications: Lymphoma/Leukemia Solid Tumors Sickle Cell Disease Beta-Thalassemia Source: Evaluate Pharma as of August 2023 Third Wave 8 Potential Approved Partner Programs Launch Potential: 2028-2030 SPL Programs: Undisclosed Example Indications: Solid Tumors Lymphoma/Leukemia Multiple Myeloma Sickle Cell Disease Beta-Thalassemia 12 Fourth Wave 20+ Additional Preclinical Partner Programs Launch Potential: 2030+ Example Indications: Solid Tumors Autoimmune Diseases Neurodegenerative Diseases Genetic Diseases Lymphoma/Leukemia M MaxCyte Fifth Wave Additional Licensed Programs and New Partnerships Signed Launch Potential: 2032+ © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation